Bayer Inc. v. Apotex Inc., 2014 FC 436 (Drospirenone*)
Justice Hughes - 2014-05-07
Read full decision. Automatically generated summary:
This is an application brought by the Applicants Bayer Inc. and Bayer Pharma Aktiengesellschaft, collectively Bayer, under the provisions of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (NOC Regulations), to prohibit the Minister of Health from issuing a Notice of Compliance to the Respondent Apotex Inc. in respect of its proposed drospirenone and ethinylestradiol combination until the expiry of Canadian Letters Patent No. 2,382,426 (the ‘426 Patent). For the reasons that follow I find that Apotex’s allegations as to non-infringement are justified thus the application is dismissed. [Note: This decision has the same neutral citation as a previously published decision.]
Decision relates to:
- T-1579-12 - BAYER INC. ET AL v. APOTEX INC. ET AL